Fujifilm Corporation is investing more than $2 billion to establish a new large-scale cell culture production site in the U.S. to accelerate the growth of its biopharmaceutical contract development and manufacturing business.   Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm Corporation, with development and manufacturing facilities across the U.S., UK, and Denmark will operate the new facility. This new facility will offer large-scale cell culture manufacturing of bulk drug substan...